Actively Recruiting
Pilot Study Evaluating Safety and Imaging of 4-18F-Fluoro-1-naphthol PETCT in Graft Versus Host Disease
Led by M.D. Anderson Cancer Center · Updated on 2026-09-17
16
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of the imaging agent 4-18FFluoro-1-Naphthol 18F4FN in PETCT scans to evaluate its safety and possible side effects in people with acute or chronic graft-versus-host disease GVHD. The study aims to understand how 18F4FN PETCT imaging relates to the physical signs and severity of GVHD and whether these imaging features appear before symptoms at specific body sites. It also looks at how changes in PETCT-positive GVHD lesions respond to therapies targeting immune cells. Participants will undergo PETCT scans using the 18F4FN agent given by intravenous injection. The study includes two parts one analyzes imaging at baseline, and the other assesses imaging before starting a new systemic GVHD therapy. These scans will help correlate imaging findings with treatment effects on GVHD lesions. The study is non-randomized and involves parallel groups. During the study, participants will be monitored for safety and any adverse events related to the 18F4FN agent through about one year after enrollment. Researchers will collect data on imaging results, clinical GVHD manifestations, and treatment responses. Participants must meet specific criteria including age, kidney function, and ability to consent, and safety will be carefully tracked throughout the study period lasting until 2030.
CONDITIONS
Brief Title
A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET/CT Imaging With Graft Versus Host Disease Manifestations
Research Team
G
George L Chen, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here